Strattera Ad Division Letter “Unsubstantiated,” WLF Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has no evidence to support its claims that a recent Lilly Strattera (atomoxetine) TV ad is misleading, the Washington Legal Foundation said
You may also be interested in...
Washington Legal Foundation To Keep Eye On FDA’s Ad Division With “DDMAC Watch”
WLF will consider litigation against FDA in the case of inappropriate trends in the ad division’s warning and untitled letters. The program’s “rapid response” component will send responses to DDMAC letters specifically addressing “legally deficient or ill-advised” citations.